Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Items 501–600 of 777
Miri, S., Karkhah, S., Vajargah, P. G., Mollaei, A., Falakdami, A., Takasi, P., Zeydi, A. E., & Ghazanfari, M. J. (2022) · Jorjani Biomedicine Journal · doi:10.52547/jorjanibiomedj.10.1.84 · Cited by 3
“(34) Bubar et al., 2021 Model-informed COVID-19 vaccine prioritization strategies by age and serostatus cross- sectional survey N/A Strategies such as speeding up the vaccination process, proper public education about vaccines and disease, and adherence to the mask can be effective.”
BackgroundRoubenoff, E., Feehan, D. M., & Mahmud, A. S. (2023) · Epidemics · doi:10.1016/j.epidem.2023.100686 · Cited by 3
“We scaled the values of ui to calibrate to a specific value of R0 by optimizing a scaling factor for ui such that the argest eigenvalue of the NGM matches an assumed R0 value (Davies t al., 2020; Bubar et al., 2021; McEvoy et al., 2020).”
IMPACTO DA VACINAÇÃO CONTRA COVID-19 SOBRE A INTERNAÇÃO E DE MORTALIDADE EM IDOSOS EM ALAGOAS
Amaral, G. M. C., & Lessa, S. S. (2023) · Interfaces Científicas - Saúde e Ambiente · doi:10.17564/2316-3798.2023v9n2p180-193 · Cited by 3
Effective vaccination strategies to control COVID-19 in Korea: a modeling study
Ko, Y., Peck, K. R., Kim, Y., Kim, D.-H., & Jung, E. (2023) · Epidemiology and Health · doi:10.4178/epih.e2023084 · Cited by 3
“Similarly, Bubar et al. [8] evaluated the effectiveness of various vaccine prioritization strategies, taking serostatus into consideration.”
BackgroundBilgin, G. M., Lokuge, K., Jabbie, E., Munira, S. L., & Glass, K. (2023) · BMC Public Health · doi:10.1186/s12889-023-17374-0 · Cited by 4
Planning Interventions in a Controlled Pandemic: The COVID-19 Case
Galante, F., Ravazzi, C., Garetto, M., & Leonardi, E. (2023) · IEEE Transactions on Network Science and Engineering · doi:10.1109/tnse.2023.3343807 · Cited by 3
“While considering vaccinations, one has to distinguish between vaccinated who are protected by the vaccine, vaccinated without protection against COVID-19 and unvaccinated because of a positive serotest or refusal to vaccinate [16].”
Deng, Y., He, D., & Zhao, Y. (2024) · Applied Mathematical Modelling · doi:10.1016/j.apm.2024.05.018 · Cited by 3
Dynamic Vaccine Allocation for Control of Human-Transmissible Disease
Lyu, M., Chang, C., Liu, K., & Hall, R. W. (2024) · Vaccines · doi:10.3390/vaccines12091034 · Cited by 3
“However, while the inclusion of serological testing improves the precision of vaccine allocation, it also introduces complexities related to the availability, accuracy, and timeliness of serological tests [18].”
BackgroundInfluentialInfluenza vaccine allocation in tropical settings under constrained resources
Servadio, J. L., Choisy, M., Thái, P. Q., & Boni, M. F. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae379 · Cited by 3
“Prioritization based on advanced age or health status was likewise reflected in COVID-19 vaccination rollouts in 2021 (26, 27).”
Berec, L., Levínský, R., Weiner, J., Šmíd, M., Neruda, R., Vidnerová, P., & Suchopárová, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-11250-4 · Cited by 3
Briffoteaux, G., Ragonnet, R. R., Tomenko, P., Mezmaz, M., Melab, N., & Tuyttens, D. (2022) · Communications in computer and information science · doi:10.1007/978-3-031-22039-5_16 · Cited by 3
Co-circulation of two viral populations under vaccinationPreprint
Acuña‐Zegarra, M. A., Núñez‐López, M., Comas‐García, A., Santana-Cibrian, M., & Velasco‐Hernández, J. X. (2021) · medRxiv · doi:10.1101/2020.12.29.20248953 · Cited by 3
“The COVID-19 vaccines will not be deployed to the general population in many parts of the world until later in 2021 [4, 5] and, from now to that unknown date, humanity must rely in the use of non-pharmaceutical interventions (NPI) to prevent contagion and to control a likely rebound in the number of cases.”
BackgroundSIR-based model with multiple imperfect vaccinesPreprint
Aguilar-Canto, F. J., de León, U. A.-P., & Avila-Vales, E. J. (2021) · medRxiv · doi:10.1101/2021.05.07.21256860 · Cited by 3
“1 Introduction During the ongoing COVID-19 pandemic, caused by the β-Coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), multiple strategies have been proposed to control the outbreak, including social distancing, lockdown, travel restrictions, remote schooling [6], most of them with sever…”
BackgroundParameter Estimation for the SEIR Model Using Recurrent NetsPreprint
Fan, C. C., Meng, Y., Sun, X., Wu, F. L., Zhang, T., & Li, J. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2105.14524 · Cited by 4
“Since the outbreak of Covid-19, the SEIR model has been widely used to model the Covid-19 spread around the world [9, 12, 13] and provide important insights regarding isolation policies [4, 5, 8] and vaccine delivery strategies [3, 11].”
MethodVaccination strategies in structured populations under partial immunity and reinfectionPreprint
Rodríguez-Maroto, G., Atienza-Diez, I., Ares, S., & Manrubia, S. C. (2021) · medRxiv · doi:10.1101/2021.11.23.21266766 · Cited by 4
Meza, R., & Jeon, J. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac099 · Cited by 3
Did Risk-based or Age-based Vaccine Prioritization for Covid-19 Save More Lives?Preprint
Smits, J., Malik, A. A., Elharake, J. A., Mobarak, A. M., & Omer, S. B. (2022) · medRxiv · doi:10.1101/2022.10.18.22281237 · Cited by 3
“For the “death” outcome, prioritizing high-risk individuals was as effective as prioritizing those aged 60+. Bubar et al (2021) used a mathematical model to predict the likely effects of age-stratified prioritization strategies, and predicted that mortality would be minimized when people over age…”
BackgroundResultImmune boosting bridges leaky and polarized vaccination modelsPreprint
Park, S. W., Li, M., Metcalf, C. J. E., Grenfell, B. T., & Dushoff, J. G. (2023) · medRxiv · doi:10.1101/2023.07.14.23292670 · Cited by 4
Parallel surrogate-based algorithms for solving expensive optimization problems
Briffoteaux, G. (2022) · theses.fr (ABES) · doi:10.70675/66a49a54z0033z4dcdz9504ze0ca42de8f1b · Cited by 3
Süner, A. F., Ergör, G., Çağlayan, D., Türe, N., Güzel, I., Irmak, Ç., IŞIK, E., Appak, Ö., Çelik, M., Öztürk, G., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70003 · Cited by 4
25 Models in the COVID-19 Pandemic
Imai, N., Baguelin, M., & Ferguson, N. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_37 · Cited by 2
Model-based estimates of age-structured SARS-CoV-2 epidemiology in households
Toth, D. J. A., Sheets, T. R., Beams, A. B., Ahmed, S. M., Seegert, N., Love, J., Keegan, L. T., & Samore, M. H. (2024) · BMC Public Health · doi:10.1186/s12889-024-20308-z · Cited by 2
“Understanding differences in transmission among and between different age groups, and the mechanisms by which those differences might arise, can shed light on the benefits of age-group targeting of transmission-interruption measures, including vaccination [14].”
Defilippo, A., Lomoio, U., Puccio, B., Veltri, P., & Guzzi, P. H. (2025) · Social Network Analysis and Mining · doi:10.1007/s13278-025-01556-2 · Cited by 4
How new approach methods are reshaping virology research
Liu, M., Faris, J. G., Panfil, A. R., & Warren, C. J. (2026) · Journal of Virology · doi:10.1128/jvi.01326-25 · Cited by 2
“…transmission models aided in the understanding of testing, quaran tining, and social distancing strategies during early phases of the COVID-19 pandemic (95, 115, 117), and informed public health officials as to what populations should be prioritized when vaccine supplies were limited (114).”
Reopening California: Seeking Robust, Non-Dominated COVID-19 Exit Strategies
de Lima, P. N., Lempert, R. J., Vardavas, R., Baker, L., Ringel, J., Rutter, C. M., Ozik, J., & Collier, N. T. (2021) · RAND Corporation eBooks · doi:10.7249/wra1080-2 · Cited by 2
Comparing the efficiency of forward and backward contact tracing
Juul, J. L., & Strogatz, S. H. (2023) · Physical review. E · doi:10.1103/physreve.108.034308 · Cited by 2
“Topics included vaccination prioritization strategies [26], the importance of accuracy and turnaround time in diagnostic tests [21, 27, 28], how standard confidence intervals can obscure”
BackgroundOfori, S. K., Schwind, J. S., Sullivan, K. L., Chowell, G., Cowling, B. J., & Fung, I. C. (2024) · Pathogens and Global Health · doi:10.1080/20477724.2024.2313787 · Cited by 2
“Given that the objective of this study was to provide evidence on the impact of increasing vaccination coverage and reducing the transmission rate through NPIs across a range of scenarios to guide public health decisions, we did not fit our model to any case, death, or other time series data [65].”
BackgroundDetailed parallel social modeling for the analysis of COVID-19 spread
Martínez, A. C., Carretero, J., & Singh, D. E. (2024) · The Journal of Supercomputing · doi:10.1007/s11227-023-05881-1 · Cited by 2
“Bubar et al. [28] compare five age-stratified prioritization strategies in terms of cumulative incidence, mortality, and years of life lost.”
Lim, Y., Ko, Y., Mendoza, V. M. P., Mendoza, R., Lee, J., & Jung, E. (2024) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2024005 · Cited by 2
Optimizing vaccine site locations while considering travel inconvenience and public health outcomes
Zhang, S., Suen, S., Yu, H., Dessouky, M. M., & Ordóñez, F. (2026) · Health Care Management Science · doi:10.1007/s10729-026-09778-2 · Cited by 2
Rojas, A. S. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21050567 · Cited by 2
“An example was the prioritisation of vaccinations for them [94] Still, what happened during the pandemic can be seen as an opportunity to reframe older age as a period of possibilities, to stress the importance of exercising, to think of older people as capable people, and to see the economic and…”
BackgroundPetrie, J. G., Pattinson, D., King, J. P., Neumann, G., Guan, L., Jester, P. J., Rolfes, M. A. R., Meece, J. K., Kieke, B. A., Belongia, E. A., et al. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae125 · Cited by 2
Optimal vaccine allocation strategy: Theory and application to the early stage of COVID-19 in Japan
Kuniya, T., Nakata, T., & Fujii, D. (2024) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2024277 · Cited by 2
Zhu, J., Wang, Q., & Huang, M. (2024) · Systems · doi:10.3390/systems12080286 · Cited by 2
“Bubar et al. [35] modeled COVID-19 transmission dynamics using an SEIR-type model and compared five age-stratified vaccine prioritization strategies in a limited-resource setting.”
MethodFamiliar-Macedo, D., de Azeredo, E. L., de Lemos, E. R. S., Damasco, P. V., & de‐Oliveira‐Pinto, L. M. (2025) · Vaccines · doi:10.3390/vaccines13020101 · Cited by 2
“These questions are particularly relevant in the search for new vaccines, considering the emergence of many viral variants, limited vaccine supply, and the inequitable distribution of vaccines worldwide [16].”
Raskin, N., Hiligsmann, M., Luyten, J., Tubeuf, S., Grigoriev, A., & Kessels, R. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126997 · Cited by 2
The effect of outcome choice on vaccine dose allocation: a modelling study
Burch, E., Christensen, H., & Brooks‐Pollock, E. (2025) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2025.112156 · Cited by 2
Castioni, P., & Arenas, À. (2025) · Physical review. E · doi:10.1103/51fg-4rhx · Cited by 2
“…remains extremely relevant, and in recent years we have seen a flourishing of papers dedicated to optimizing control interventions (both pharmaceutical [2, 3] or non-pharmaceutical [4–6]), where the criterion to define optimality heavily depends on the model and on the choice of the cost function.”
Nguyen, D. H., Tran, L. B., Viên, N. T., Hashan, M. R., Tripathi, A., Han, S. M., Nguyen, A. H., Trinh, N. B., Shabbo, E. E., Thang, D. X., et al. (2026) · Tropical Medicine and Health · doi:10.1186/s41182-025-00877-4 · Cited by 2
“[11].”
Janušonis, V., Makarenko, B., & Janušonytė, H. (2021) · Tiltai · doi:10.15181/tbb.v86i1.2261 · Cited by 3
Gedikli, T., & Ervural, B. Ç. (2021) · Lecture notes in mechanical engineering · doi:10.1007/978-3-030-90421-0_6 · Cited by 2
Optimal exit strategy design for COVID-19
Giamberardino, P. D., & Iacoviello, D. (2021) · International Conference on System Theory, Control and Computing (ICSTCC) · doi:10.1109/icstcc52150.2021.9607220 · Cited by 2
Lin, Y., Li, Y., Duan, Q., Lei, H., Tian, D., Xiao, S., Jiang, Y., Sun, C., Du, X., Shu, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27783 · Cited by 3
“First, to minimize the deaths, Bubar et al.(12) recommended older adults enjoy a vaccine priority due to its higher fatality rate.”
BackgroundSaraswat, B., Ansumali, S., & Prakash, M. K. (2021) · Current Science · doi:10.18520/cs/v120/i11/1698-1704 · Cited by 2
Robust Decision Making in Health Policy: Applications to COVID-19 and Colorectal Cancer
de Lima, P. N. (2022) · RAND Corporation eBooks · doi:10.7249/rgsda2531-1 · Cited by 2
Kashani, H., Sharif, S. V., Hosseini, S., & Hekmatian, M. A. (2022) · Springer series on bio- and neurosystems · doi:10.1007/978-3-031-10031-4_16 · Cited by 2
Regional policy coordination of pandemic responses using an iterative mobility-driven algorithm
Baghersad, M., Gumus, G., Huang, C., & Behara, R. S. (2023) · Regional Studies · doi:10.1080/00343404.2023.2220749 · Cited by 2
“Identifying highly connected communities irrespective of existing jurisdictions will help better coordinate their efforts to improve vaccination rates and address any access inequities (Bubar et al., 2021).”
BackgroundEffectiveness of vaccination and quarantine policies to curb the spread of COVID-19
Jang, G. H., Kim, S. J., Lee, M. J., & Son, S. (2024) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2024.129580 · Cited by 2
Modeling the effects of disparities in vaccine efficacies and rollout rates
Bargo, M. C. R., Sambayan, R. R., Improso, H. R. L. D., & Lope, J. E. C. (2024) · AIP conference proceedings · doi:10.1063/5.0212659 · Cited by 2
Morrison, D. E., Nianogo, R. A., Manuel, V., Arah, O. A., Anderson, N., Kuo, T., & Inkelas, M. (2021) · medRxiv · doi:10.1101/2021.02.27.21252535 · Cited by 2
Addressing the COVID-19 Pandemic: Comparing Alternative Value FrameworksPreprint
Ferranna, M., Sevilla, J. P., & Bloom, D. E. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3803725 · Cited by 3
Adibi, A., Mozafarihashjin, M., & Sadatsafavi, M. (2021) · medRxiv · doi:10.1101/2021.04.11.21255138 · Cited by 2
A conceptual approach to the rationale for SARS-CoV-2 vaccine allocation prioritisation
Vasconcelos, M. K., Marazia, C., Koniordou, M., Fangerau, H., Drexler, I., & Awuah, A. A.-A. (2021) · Pathogens and Global Health · doi:10.1080/20477724.2021.1932136 · Cited by 2
“The aim of prioritization is to allocate available vaccine doses where their impact on morbidity and mortality is expected to be highest[8].”
BackgroundInfluentialPongou, R., Tchuente, G., & Tondji, J. (2021) · RePEc: Research Papers in Economics · doi:10.48550/arxiv.2110.10230 · Cited by 4
“…plays an essential role in the level of infection spread and information diffusion (see, for example, Keeling & Eames (2005), Pongou & Serrano (2013), Pongou & Serrano (2016), and recently, Kuchler et al. (2020), Harris (2020), Chang et al. (2021), and Bubar et al. (2021), among others).”
BackgroundBayesian data assimilation for estimating epidemic evolution: a COVID-19 studyPreprint
Yang, X., Wang, S., Xing, Y., Li, L., Xu, R. Y. D., Friston, K. J., & Guo, Y. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2101.01532 · Cited by 2
Vaccine Allocation Priorities Using Disease Surveillance and Economic Data
Malani, A., Soman, S., Ramachandran, S., Chen, A. P., & Lakdawalla, D. (2022) · National Bureau of Economic Research · doi:10.3386/w29682 · Cited by 2
“Some also look at the impact on infections (Bubar et al., 2021; Buckner et al., 2021; Chapman et al., 2021; Chen et al., 2021) and hospitalizations (Chen et al.”
BackgroundInfluentialFeng, M., Tian, L., & Zhou, C. (2021) · SSRN Electronic Journal · doi:10.1101/2021.10.11.21264836 · Cited by 2
Vaccination strategies in structured populations under partial immunity and reinfectionPreprint
Rodríguez-Maroto, G., Atienza-Diez, I., Ares, S., & Manrubia, S. C. (2022) · Research Square · doi:10.21203/rs.3.rs-1803270/v1 · Cited by 2
Więcek, W., Johnston, D., Dulka, T., Toomey, D., & Lewis, E. (2023) · medRxiv · doi:10.1101/2023.06.16.23291442 · Cited by 2
Pantha, B., Mohammed-Awel, J., & Vaidya, N. K. (2023) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqad007 · Cited by 2
Optimal Vaccination for Contagious Diseases with Seasonal Transmission
Gavish, N., & Katriel, G. (2026) · Bulletin of Mathematical Biology · doi:10.1007/s11538-026-01741-0 · Cited by 1
Hoque, T., & Bhowmik, S. K. (2025) · Partial Differential Equations in Applied Mathematics · doi:10.1016/j.padiff.2025.101308 · Cited by 1
Ntsham, X., Nkosi, V., & Ledibane, T. D. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22111707 · Cited by 1
“Initially, vaccination initiatives prioritised healthcare workers (HCWs), older people, and individuals with pre-existing conditions [9].”
Lin, L., Demirhan, H., Eizenberg, P., Trauer, J. M., & Stone, L. (2026) · Journal of The Royal Society Interface · doi:10.1098/rsif.2025.0839 · Cited by 1
Gül, N. N., Taheri, S., de Leeuw, S., & Kian, R. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118918 · Cited by 1
Optimizing vaccination strategies under uncertainty to prevent epidemics
Ntaimo, L., Mzyece, M., & Katerere, D. R. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1761731 · Cited by 1
Future-oriented chance prioritarianism: survival prospects as the distributive currency
Żuradzki, T. (2026) · Medicine Health Care and Philosophy · doi:10.1007/s11019-026-10353-3 · Cited by 1
“However, according to model-based studies, it may also have reduced the total number of years of life lost in the population, given the steep age gradient in COVID-19 mortality (Bubar et al. 2021).”
Minimisation of Vaccine Inventory Costs Based on a Discretised SIV-Type Epidemic Model
Hoseana, J. (2026) · Lecture notes in networks and systems · doi:10.1007/978-3-032-20362-5_7 · Cited by 1
A dual-stochastic network epidemic model with logarithmic Ornstein-Uhlenbeck process and white noise
Wang, Y., Liu, X., Cao, H., Nie, L., & Wang, W. (2026) · Nonlinear Dynamics · doi:10.1007/s11071-026-12760-w · Cited by 1
“[22]developedasusceptible-infected-recovered-dead (SIRD) framework to analyze early outbreak dynamics, while Bubar et al. [23] demonstrated how age-and serostatus-based vaccine prioritization can minimize cumulative mortality.”
Epidemic Vulnerability Index for Effective Vaccine Distribution Against Pandemic
Lee, H., Kang, M., Li, Y., Seo, D., & Kim, D.-H. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-91415-8_3 · Cited by 1
COVID-19 Vaccination: The Voice of Adolescents and Young Adults
Branquinho, C., Machado, M. D. C., Noronha, C., & de Matos, M. G. (2021) · Análisis y Modificación de Conducta · doi:10.33776/amc.v47i176.5596 · Cited by 1
Expanding COVID-19 Vaccine Availability: Role for Combined Orthogonal Serology Testing (COST)
Narasimhan, M., Mahimainathan, L., Araj, E., Clark, A. E., Wilkinson, K., Yekkaluri, S., Tiro, J. A., Lee, F. M., Balani, J. P., Sarode, R., et al. (2021) · Vaccines · doi:10.3390/vaccines9040376 · Cited by 1
“[13] modeled and reported that the incorporation of serological testing and population seroprevalence could efficiently help prioritize vaccination across countries [13].”
BackgroundAllocating vaccines to remote and on-site workers in the tradable sector
Czaller, L., Tóth, G., & Lengyel, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-08043-0 · Cited by 1
Shah, S. B., Chawla, R., Rawal, S. K., Mehta, A., & Parkash, A. (2022) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20221189 · Cited by 1
ten Have, H. (2022) · Advancing global bioethics · doi:10.1007/978-3-030-91491-2_8 · Cited by 1
The role of connectivity on COVID-19 preventive approaches
Pina, V. M., Nava-Trejo, J., Tóbiás, A., Nzabarushimana, É., Casanova, A. G., & González-Casanova, I. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273906 · Cited by 1
“[10] evaluated these two strategies in different contexts and demonstrated that, in most scenarios, years of life lost were minimized by strategies that prioritized adults over 60 years, even as incidence was minimized when younger adults were prioritized.”
Emerging Europe's chronic distrust: Lessons from the region's COVID puzzle
(2022) · Budapesti Corvinus Egyetem eBooks · doi:10.14267/978-963-503-927-2 · Cited by 2
AI, Epidemiology and Public Health in the Covid Pandemic
Lefèvre, T., Colineaux, H., Morgand, C., Tournois, L., & Delpierre, C. (2022) · Springer eBooks · doi:10.1007/978-3-031-08506-2_13 · Cited by 4
Quantifying the role of airborne transmission in the spread of COVID-19
Hayden, M., Morrow, B., Yang, W., & Wang, J. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023027 · Cited by 1
Carobene, A., Famiglini, L., Sabetta, E., Naclerio, A., & Banfi, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-08506-2_5 · Cited by 1
Optimal Capacity-Constrained COVID-19 Vaccination for Heterogeneous Populations
Arghal, R., Bidokhti, S. S., & Sarkar, S. S. (2022) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc51059.2022.9992682 · Cited by 1
“[29] considers a few age-based vaccination policies in an augmented compartmental model.”
BackgroundVelasco‐Hernández, J. X. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95064-0.00002-6 · Cited by 1
Smith, M. J., Enns, E. A., White, L. A., Gilbertson, M. L. J., & Craft, M. E. (2023) · Royal Society Open Science · doi:10.1098/rsos.221122 · Cited by 1
A Mathematical Model for the Effect of Vaccination on COVID-19 Epidemic Spread
Singh, A. K., Rai, S., & Bajpai, M. K. (2023) · Lecture notes in electrical engineering · doi:10.1007/978-981-99-0189-0_9 · Cited by 1
A hospital demand and capacity intervention approach for COVID-19
Yperen, J. V., Campillo-Funollet, E., Inkpen, R., Memon, A., & Madzvamuse, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283350 · Cited by 2
Mobile Vaccination Clinic Routing Problem
Yucesoy, E., Çoban, E., & Balcik, B. (2023) · International Conference on Industrial Engineering and Operations Management (IEOM) · doi:10.46254/an12.20220212 · Cited by 1
“(2021), and Bubar et al. (2021) analyze the effect of prioritizing different groups on different performance metrics, where detailed compartmental models are proposed in Chen et al.”
BackgroundLee, S., & Kim, S. (2023) · Vaccines · doi:10.3390/vaccines11061021 · Cited by 1
Analysis of pandemic with game methodology and numerical approximation
Matusik, R., & Nowakowski, A. (2023) · Archives of Control Sciences · doi:10.24425/acs.2023.146963 · Cited by 1
Modelling lifespan reduction in an exogenous damage model of generic disease
Tobin, R., Pridham, G., & Rutenberg, A. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-43005-0 · Cited by 1
“Researchers typically ask if it is better to vaccinate the old to reduce direct risk, or vaccinate the young to reduce overall infection prevalence 19 .”
Backgroundde León, U. A.-P., Pérez, Á. G. C., & Avila-Vales, E. J. (2024) · Electronic Research Archive · doi:10.3934/era.2024053 · Cited by 1
Balancing the benefits of vaccination: An envy-free strategy
Almeida, P. R., Sanches, V. H., & Goldman, C. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae087 · Cited by 1
“In particular, an SEIR (susceptible, exposed, infectious, recovered) model dynamics has been considered for analyzing different scenarios for the choice of the age groups at the initial period of vaccination [17].”
Periodic vaccination for post-pandemic management: Insights from and planning beyond COVID-19
Xiao, J., Ayer, T., & Chhatwal, J. (2024) · IISE Transactions on Healthcare Systems Engineering · doi:10.1080/24725579.2024.2340515 · Cited by 1
“Meanwhile, the majority of COVID-19 vaccine operations management papers have focused on the novel allocation challenges posed by the initial rollout of a two-dose vaccine (Matrajt et al., 2021; Bubar et al., 2021; Buckner et al., 2021; Mak et al., 2021).”
Ofori, S. K., Dankwa, E. A., Estrada, E. H., Hua, X., Kimani, T. N., Wade, C. G., Buckee, C. O., Murray, M. B., & Hedt‐Gauthier, B. (2024) · Tropical Medicine & International Health · doi:10.1111/tmi.13994 · Cited by 1
“Even in countries where contact survey data are available, the elderly are rarely surveyed despite experiencing the worst outcomes for diseases [56].”
BackgroundOptimal design of vaccination policies: A case study for Newfoundland and Labrador
Khoshbakhtian, F., Validi, H., Ventresca, M., & Aleman, D. M. (2024) · Operations Research Letters · doi:10.1016/j.orl.2024.107140 · Cited by 1
“Improved vaccination policies can save lives, drastically reduce the number of infectious diseases, and significantly reduce the financial costs of pandemics [4, 5].”
BackgroundScreening of potential vaccine candidates through machine learning approach
Nasir, S., Ishaq, Z., Shahid, F., Zaheer, T., Qayyum, H., & Ali, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13395-4.00016-2 · Cited by 1
Fadlyana, E., Rusmil, K., Putra, M. G. D., Fulendry, F. P., Somantri, N. K., Putri, A. D., Sari, R. M., Puspita, M., & Dewi, G. P. (2024) · Vaccines · doi:10.3390/vaccines12080938 · Cited by 2
Meireles, G. O. A. B., Silva, B. M., Freires, K. R. F. S., de Aguiar, M. A. P., & de Matos, M. A. (2024) · Saúde e Pesquisa · doi:10.17765/2176-9206.2024v17n1.e11982 · Cited by 1
COVID-19 Vaccine Distribution Patterns for Prioritized Age Group: Analysis of European Nations
Ezichi, O., Okpanachi, V. U., Jibunoh, J., Awosan, W. R., Tchoumo, P., Akande, A., Amaechi, C., Sanusi, J., Ogunsanwo, F., & Adesina, R. D. (2025) · Open Journal of Epidemiology · doi:10.4236/ojepi.2025.151001 · Cited by 1
Reconstructing the first COVID-19 pandemic wave with minimal data in England
Chen, S., Flegg, J. A., Lythgoe, K., & White, L. J. (2025) · Epidemics · doi:10.1016/j.epidem.2025.100814 · Cited by 1
A review of analytical models and methods for COVID-19: vaccination and testing
Hajj, H. E., Gzara, F., & Elhedhli, S. (2025) · INFOR Information Systems and Operational Research · doi:10.1080/03155986.2025.2513716 · Cited by 1
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.